Screening for barrett's esophagus and esophageal adenocarcinoma

Rationale, recent progress, challenges, and future directions

Sarmed S. Sami, Krish Ragunath, Prasad G Iyer

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

As the incidence and mortality of esophageal adenocarcinoma continue to increase, strategies to counter this need to be explored. Screening for Barrett's esophagus, which is the known precursor of a large majority of adenocarcinomas, has been debated without a firm consensus. Given evidence for and against perceived benefits of screening, the multitude of challenges in the implementation of such a strategy and in the downstream management of subjects with Barrett's esophagus who could be diagnosed by screening, support for screening has been modest. Recent advances in the form of development and initial accuracy of noninvasive tools for screening, risk assessment tools, and biomarker panels to risk stratify subjects with BE, have spurred renewed interest in the early detection of Barrett's esophagus and related neoplasia, particularly with the advent of effective endoscopic therapy. In this review, we explore in depth the potential rationale for screening for Barrett's esophagus, recent advances that have the potential of making screening feasible, and also highlight some of the challenges that will have to be overcome to develop an effective approach to improve the outcomes of subjects with esophageal adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)623-634
Number of pages12
JournalClinical Gastroenterology and Hepatology
Volume13
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Barrett Esophagus
Adenocarcinoma
Biomarkers
Mortality
Direction compound
Incidence
Neoplasms
Therapeutics

Keywords

  • Barrett's Esophagus
  • Esophageal Adenocarcinoma
  • Risk Stratification
  • Screening
  • Screening Tools

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Screening for barrett's esophagus and esophageal adenocarcinoma : Rationale, recent progress, challenges, and future directions. / Sami, Sarmed S.; Ragunath, Krish; Iyer, Prasad G.

In: Clinical Gastroenterology and Hepatology, Vol. 13, No. 4, 01.04.2015, p. 623-634.

Research output: Contribution to journalArticle

@article{993d23b85fdb4edabbe0757ab48d6304,
title = "Screening for barrett's esophagus and esophageal adenocarcinoma: Rationale, recent progress, challenges, and future directions",
abstract = "As the incidence and mortality of esophageal adenocarcinoma continue to increase, strategies to counter this need to be explored. Screening for Barrett's esophagus, which is the known precursor of a large majority of adenocarcinomas, has been debated without a firm consensus. Given evidence for and against perceived benefits of screening, the multitude of challenges in the implementation of such a strategy and in the downstream management of subjects with Barrett's esophagus who could be diagnosed by screening, support for screening has been modest. Recent advances in the form of development and initial accuracy of noninvasive tools for screening, risk assessment tools, and biomarker panels to risk stratify subjects with BE, have spurred renewed interest in the early detection of Barrett's esophagus and related neoplasia, particularly with the advent of effective endoscopic therapy. In this review, we explore in depth the potential rationale for screening for Barrett's esophagus, recent advances that have the potential of making screening feasible, and also highlight some of the challenges that will have to be overcome to develop an effective approach to improve the outcomes of subjects with esophageal adenocarcinoma.",
keywords = "Barrett's Esophagus, Esophageal Adenocarcinoma, Risk Stratification, Screening, Screening Tools",
author = "Sami, {Sarmed S.} and Krish Ragunath and Iyer, {Prasad G}",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.cgh.2014.03.036",
language = "English (US)",
volume = "13",
pages = "623--634",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Screening for barrett's esophagus and esophageal adenocarcinoma

T2 - Rationale, recent progress, challenges, and future directions

AU - Sami, Sarmed S.

AU - Ragunath, Krish

AU - Iyer, Prasad G

PY - 2015/4/1

Y1 - 2015/4/1

N2 - As the incidence and mortality of esophageal adenocarcinoma continue to increase, strategies to counter this need to be explored. Screening for Barrett's esophagus, which is the known precursor of a large majority of adenocarcinomas, has been debated without a firm consensus. Given evidence for and against perceived benefits of screening, the multitude of challenges in the implementation of such a strategy and in the downstream management of subjects with Barrett's esophagus who could be diagnosed by screening, support for screening has been modest. Recent advances in the form of development and initial accuracy of noninvasive tools for screening, risk assessment tools, and biomarker panels to risk stratify subjects with BE, have spurred renewed interest in the early detection of Barrett's esophagus and related neoplasia, particularly with the advent of effective endoscopic therapy. In this review, we explore in depth the potential rationale for screening for Barrett's esophagus, recent advances that have the potential of making screening feasible, and also highlight some of the challenges that will have to be overcome to develop an effective approach to improve the outcomes of subjects with esophageal adenocarcinoma.

AB - As the incidence and mortality of esophageal adenocarcinoma continue to increase, strategies to counter this need to be explored. Screening for Barrett's esophagus, which is the known precursor of a large majority of adenocarcinomas, has been debated without a firm consensus. Given evidence for and against perceived benefits of screening, the multitude of challenges in the implementation of such a strategy and in the downstream management of subjects with Barrett's esophagus who could be diagnosed by screening, support for screening has been modest. Recent advances in the form of development and initial accuracy of noninvasive tools for screening, risk assessment tools, and biomarker panels to risk stratify subjects with BE, have spurred renewed interest in the early detection of Barrett's esophagus and related neoplasia, particularly with the advent of effective endoscopic therapy. In this review, we explore in depth the potential rationale for screening for Barrett's esophagus, recent advances that have the potential of making screening feasible, and also highlight some of the challenges that will have to be overcome to develop an effective approach to improve the outcomes of subjects with esophageal adenocarcinoma.

KW - Barrett's Esophagus

KW - Esophageal Adenocarcinoma

KW - Risk Stratification

KW - Screening

KW - Screening Tools

UR - http://www.scopus.com/inward/record.url?scp=84925096803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925096803&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2014.03.036

DO - 10.1016/j.cgh.2014.03.036

M3 - Article

VL - 13

SP - 623

EP - 634

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 4

ER -